Published in J Clin Invest on February 21, 2011
Genetics of human cardiovascular disease. Cell (2012) 1.90
The Spatiotemporal Limits of Developmental Erk Signaling. Dev Cell (2017) 1.44
Hydrogen sulfide anion regulates redox signaling via electrophile sulfhydration. Nat Chem Biol (2012) 1.32
Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations? Hum Genomics (2012) 1.02
RAF1 mutations in childhood-onset dilated cardiomyopathy. Nat Genet (2014) 0.93
Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res (2012) 0.90
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Mol Cell Biol (2014) 0.81
BRAF gene: From human cancers to developmental syndromes. Saudi J Biol Sci (2014) 0.81
Raf-mediated cardiac hypertrophy in adult Drosophila. Dis Model Mech (2013) 0.79
Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am J Med Genet A (2015) 0.78
RSK3: A regulator of pathological cardiac remodeling. IUBMB Life (2015) 0.77
Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy. PLoS One (2015) 0.76
Gene-microRNA network module analysis for ovarian cancer. BMC Syst Biol (2016) 0.75
Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation. Bioorg Med Chem (2016) 0.75
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet (2003) 5.16
Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet (2005) 4.47
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J (2000) 4.09
Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child (1968) 3.05
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet (2005) 2.75
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol (2005) 2.62
Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet (2002) 2.46
Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation (2010) 2.37
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
PTPN11 mutations in LEOPARD syndrome. J Med Genet (2002) 1.91
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res (2010) 1.56
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
Genetics of RAS signaling in C. elegans. Trends Genet (1998) 1.49
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci (2010) 1.23
Signal transduction downstream from Ras in Drosophila. Cold Spring Harb Symp Quant Biol (1997) 1.07
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet (2009) 2.57
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet (2006) 2.31
Noonan syndrome. Lancet (2013) 2.13
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood (2005) 1.80
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat (2004) 1.80
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet (2006) 1.78
A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71
Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat (2007) 1.56
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol (2011) 1.55
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet (2010) 1.53
NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet (2005) 1.53
Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet (2008) 1.50
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat (2009) 1.49
Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J Clin Invest (2011) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer (2009) 1.36
Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur J Hum Genet (2009) 1.22
Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesis. J Clin Endocrinol Metab (2006) 1.21
Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A (2005) 1.19
SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat (2011) 1.12
Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. Am J Med Genet A (2009) 1.10
Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. Am J Med Genet A (2011) 1.07
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. Hum Mol Genet (2006) 1.07
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem (2009) 1.07
Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum Mol Genet (2008) 1.04
A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene underlies Myhre syndrome. Am J Hum Genet (2012) 1.04
Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood (2012) 1.01
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res (2004) 0.99
Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet (2008) 0.94
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood (2011) 0.94
Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. Am J Med Genet A (2009) 0.93
Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) (2006) 0.93
Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. Hum Mol Genet (2009) 0.90
ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood (2010) 0.90
Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am J Med Genet A (2009) 0.89
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2. Proteins (2007) 0.88
Childhood onset tubular aggregate myopathy associated with de novo STIM1 mutations. J Neurol (2014) 0.88
Loss of function of the E3 ubiquitin-protein ligase UBE3B causes Kaufman oculocerebrofacial syndrome. J Med Genet (2013) 0.87
Long term memory profile of disorders associated with dysregulation of the RAS-MAPK signaling cascade. Behav Genet (2011) 0.86
Behavioral profile in RASopathies. Am J Med Genet A (2014) 0.84
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet (2006) 0.84
A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Am J Med Genet A (2014) 0.82
Phenotypic variability associated with the invariant SHOC2 c.4A>G (p.Ser2Gly) missense mutation. Am J Med Genet A (2014) 0.82
Rat nicastrin gene: cDNA isolation, mRNA variants and expression pattern analysis. Brain Res Mol Brain Res (2005) 0.82
Prevalence of sequence variants in the RAS-mitogen activated protein kinase signaling pathway in pre-adolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet (2012) 0.81
Clinical lumping and molecular splitting of LEOPARD and NF1/NF1-Noonan syndromes. Am J Med Genet A (2007) 0.81
Novel SMAD4 mutation causing Myhre syndrome. Am J Med Genet A (2014) 0.81
Early fetal death associated with compound heterozygosity for Noonan syndrome-causative PTPN11 mutations. Am J Med Genet A (2007) 0.79
Transcriptional hallmarks of Noonan syndrome and Noonan-like syndrome with loose anagen hair. Hum Mutat (2012) 0.79
Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. Clin Cancer Res (2008) 0.79
Behavioral phenotype in Costello syndrome with atypical mutation: a case report. Am J Med Genet B Neuropsychiatr Genet (2014) 0.78
Geroderma osteodysplastica maps to a 4 Mb locus on chromosome 1q24. Am J Med Genet A (2008) 0.78
Reactive oxygen species and epidermal growth factor are antagonistic cues controlling SHP-2 dimerization. Mol Cell Biol (2012) 0.78
Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome. Hum Genet (2002) 0.78
Acute lymphoblastic leukaemia in Noonan syndrome. Br J Haematol (2006) 0.78
Loss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemia. Br J Haematol (2012) 0.77
Atrioventricular canal defect in patients with RASopathies. Eur J Hum Genet (2012) 0.77
GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome). Am J Med Genet A (2013) 0.77
Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome. J Biol Chem (2012) 0.77
A competitive polymerase chain reaction-based approach for the identification and semiquantification of mitochondrial DNA in differently heat-treated bovine meat and bone meal. J Food Prot (2003) 0.76
Hyperthrophic cardiomyopathy and the PTPN11 gene. Am J Med Genet A (2005) 0.76
Hydrops fetalis in a preterm newborn heterozygous for the c.4A>G SHOC2 mutation. Am J Med Genet A (2014) 0.76
Increased sleep spindle activity in patients with Costello syndrome (HRAS gene mutation). J Clin Neurophysiol (2011) 0.75
Efficient one-step chromatographic purification and functional characterization of recombinant human Saposin C. Protein Expr Purif (2011) 0.75
Progressive extreme heterotopic calcification. Am J Med Genet A (2013) 0.75
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia. Leuk Res (2010) 0.75